SLC5A2 and heart failure: Moreover, in the Dapa-heart failure trials in the patients with heart failure with decreased ejection fraction (HFrEF), the SGLT2 inhibitor (e.g., Dapa) presents an obvious cardiovascular benefit, regardless of patients with/without T2D [10].